Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS +1.29%84 3-Year ROIIC % is 10.27 as of Dec. 2025, which is 66% above its 10-year median of 6.20. GuruFocus rates MIL:ARBS with a GF Score™ of 84/100 and a GF Value™ of €2.92 (Fairly Valued). Among 1,319 Biotechnology companies, Arterra Bioscience SpA ranks better than 61.26% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Arterra Bioscience SpA's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 10.27%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Arterra Bioscience SpA's 3-Year ROIIC % or its related term are showing as below:
MIL:ARBS's 3-Year ROIIC % is ranked better than 61.26% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs MIL:ARBS: 10.27
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Arterra Bioscience SpA 3-Year ROIIC % Related Terms
Arterra Bioscience SpA 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's 3-Year ROIIC % falls into.
Arterra Bioscience SpA's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 2.034 (Dec. 2025) - 1.3393038 (Dec. 2022) )
/
( 12.64 (Dec. 2025) - 5.875 (Dec. 2022) )
=
0.6946962
/
6.765
=
10.27%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Arterra Bioscience SpA (MIL:ARBS) has a 3-Year ROIIC % of 10.27 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arterra Bioscience SpA and its competitors. This is 66% above median its historical median of 6.20. According to the industry distribution chart, Arterra Bioscience SpA ranks #511 out of 1319 companies in the Biotechnology industry, placing it in the top 38.7%.
Is Arterra Bioscience SpA's 3-Year ROIIC % too high?
Arterra Bioscience SpA's current 3-Year ROIIC % of 10.27 is 66% above median its 10-year median of 6.20. Based on the distribution chart, Arterra Bioscience SpA ranks #511 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arterra Bioscience SpA has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #511 out of 1319 companies for 3-Year ROIIC %. This puts Arterra Bioscience SpA in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current 3-Year ROIIC % is 10.27, which is 66% above median its own 10-year median of 6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.92, compared to a current price of €3.14 — trading 7.5% above its estimated fair value. The current 3-Year ROIIC % is 10.27, which is 66% above median its 10-year median of 6.20. Arterra Bioscience SpA's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current 3-Year ROIIC % is 10.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.14 is trading 7.5% above its estimated GF Value™ of €2.92.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
3-Year ROIIC %: 10.27 (66% above median its 10-year median of 6.20)
GF Value™: €2.92 vs. price of €3.14 (7.5% above fair value)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
84GF Score
Get the complete analysis for MIL:ARBS
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
